It has been approved by the China National Medical Products Administration for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring sensitive EGFR mutations and the T790M resistance mutation.[2,3] Furmonertinib has a broader safety window due to its unique trifluoroethoxypyridine structure. This evidence concerns the gene EGFR and non-small cell lung carcinoma.